Bio Break: Drug-Device Combination Products
In this episode of Bio Break, Joris and Nick explore the increasingly important world of drug-device combination products, discussing what they are, why they matter, and the unique challenges associated with their development. As modern pharmaceuticals become more complex, the role of engineered medical devices in delivering these therapies safely and effectively has never been more critical.
Joris begins by defining combination products as therapeutic solutions that combine a medical device with a pharmaceutical under a single regulatory umbrella. He explains why this approach, while more complex, is necessary for modern biologics, such as gene therapies, which require precise delivery to specific parts of the body—like the brain—where traditional methods fall short.
Key takeaways from the episode include:
- Why Combine Drugs and Devices?: Combination products are often essential for biologics and viscous therapies, which require bespoke devices for controlled, targeted delivery. For example, wearable injectors allow patients to administer viscous drugs over long periods without discomfort or traditional syringes.
- Regulatory Challenges: Combining a device and a drug introduces additional regulatory considerations, particularly aligning medical device development timelines with pharmaceutical clinical trial phases. Joris highlights how phase one trials often use off-the-shelf devices, but by phase two, the bespoke medical device must be integrated to validate both the drug and the device’s safety and efficacy.
- Device Engineering for Precision Delivery: Nick illustrates the need for tailored devices that can handle challenges like viscous fluids, using honey as a relatable example. Such precision-engineered devices ensure therapies are delivered effectively, making the drug and device interdependent for success.
The conversation highlights how collaboration between pharmaceutical and medical device developers is critical to meeting clinical milestones and achieving regulatory approval.
This episode is essential viewing for developers, innovators, and healthcare professionals working on combination products. Discover how pairing medical devices with pharmaceuticals enables groundbreaking therapies and unlocks new possibilities for patient care.
Drug-Device Combination Products – Navigating Complexity
Related Resources
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.
Nigel Syrotuck breaks down the realistic medical device V&V cost and schedule for terminally sterilized devices, picking up after design freeze and walking through each major phase of the process.
Nigel Syrotuck examines the hidden medical device sterilization costs that many development teams overlook when estimating the true cost of producing a terminally sterilized device.